Being Patient hosted a live talk with WRAP leaders and producers of the independent documentary, DETERMINED, on September 1, 2021. WRAP’s principal investigator Sterling Johnson, PhD, and Gina Green-Harris, MBA, director of the Wisconsin Alzheimer’s Institute Regional Milwaukee Office, joined the talk to discuss WRAP insights and study findings and recruitment strategies. Therese Barry-Tanner, producer …
Thank you to our 2021 externs! Wisconsin Alzheimer’s Institute offers a Summer Externship program for first-year medical students at UW School of Medicine and Public Health, encouraging these students to better understand the needs of older patients and helping them understand the need for geriatricians in our communities. The students are offered exposure to clinical …
Maria Mora Pinzon, MD, MS, presented “Barriers to Diagnosis of Alzheimer’s Disease Among Latinx Individuals” at the August 18 Wednesday Nite @ The Lab livestream. Dr. Mora Pinzon is a primary care research fellow at the UW–Madison Department of Family Medicine and Community Health, a scientist with the Wisconsin Alzheimer’s Institute (WAI), and a REC scholar in …
The Brown County Dementia Friendly Community Coalition is hosting a series of free virtual classes with a goal of increasing awareness of perspectives on dementia in Wisconsin’s Black, Latinx and Native American communities. Gina Green-Harris, MBA, will present at the upcoming Brown County Culture and Equity in Dementia Care virtual education series. Green-Harris is director …
The world’s largest and most prestigious Alzheimer’s disease conference is underway this week, and UW Alzheimer’s disease researchers are attending in high numbers, leading several important discussions.
WAI scientist Maria Mora Pinzon, PhD, recently discussed the health disparity on Chicago, Ill media outlets.
WAI Director Cynthia Carlsson, MD, MS, leads the AHEAD study.
Thank you NBC15 for featuring the guide and Dr. Mora Pinzon’s contributions.
Art Walaszek, MD, public health leader for WAI, was a guest on WPR to discuss the Alzheimer’s disease
drug aducanumab and its approval by the FDA.
On June 7, the U.S. Food and Drug Administration (FDA) approved the drug aducanumab for the treatment of Alzheimer’s disease. Read a breakdown on what this means for people living with Alzheimer’s disease and family caregivers.